Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG FLEXTOUCH.
NOVOLOG FLEXPEN vs NOVOLOG FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
None Documented
None Documented
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Category C
Category C
Insulin Analog
Insulin Analog